Hier steht ein Titel. Dieser Titel kann auch drei Zeilen haben. - PowerPoint PPT Presentation

Loading...

PPT – Hier steht ein Titel. Dieser Titel kann auch drei Zeilen haben. PowerPoint presentation | free to view - id: 272a02-ZDc1Z



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Hier steht ein Titel. Dieser Titel kann auch drei Zeilen haben.

Description:

... International ... MAJOR THREATS TO PUBLIC HEALTH. 2. Potentially new and re-emerging ... and access to information. Brokering research into policy. ... – PowerPoint PPT presentation

Number of Views:186
Avg rating:3.0/5.0
Slides: 43
Provided by: cma143
Category:

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Hier steht ein Titel. Dieser Titel kann auch drei Zeilen haben.


1
ZUSAMMENARBEIT Gesundheit und Forschung
zugunsten kleiner und mittlerer Unternehmen
(KMUs) im 7. EU-Rahmenprogramm Ylva
Huber Bereich Europäische und Internationale
Programme FFG Österreichische
Forschungsförderungsgesellschaft
2
Inhalt
  • Das 7. Rahmenprogramm im Überblick
  • Themen der ersten Ausschreibungen zu Gesundheit
  • Forschung zugunsten kleiner und mittlerer
    Unternehmen (KMU)

3
Inhalt
  • Das 7. Rahmenprogramm im Überblick
  • Themen der ersten Ausschreibungen zu Gesundheit
  • Forschung zugunsten kleiner und mittlerer
    Unternehmen (KMU)

4
(No Transcript)
5
Instrumente im 7. RP
7. EU-Rahmenprogramm 6. EU-Rahmenprogramm
Verbundprojekte (Collaborative Projects) Integrierte Projekte (IP) Gezielte Forschungsprojekte (STREPs)
Exzellenznetze (NoE) Exzellenznetze (NoE)
Koordinierungsmaßnahmen (CA) Koordinierungsmaßnahmen (CA)
Unterstützungsmaßnahmen (SSA) Unterstützungsmaßnahmen (SSA)
Unterstützung für Ausbildung und Karriereentwicklung (Marie-Curie) Unterstützung für Ausbildung und Karriereentwicklung (Marie-Curie)
Einzelprojekte im ERC (Programm Ideas)
KMU spezifische Maßnahmen KMU spezifische Maßnahmen
Artikel 169 Artikel 169
ERA-NET und ERA-NET PLUS ERA-NET
Gemeinsame Technologieinitiativen (JTI)
6
Die Ausschreibungen sind geöffnet!
rp7.ffg.at
7
Inhalt
  • Das 7. Rahmenprogramm im Überblick
  • Themen der ersten Ausschreibungen zu Gesundheit
  • Forschung zugunsten kleiner und mittlerer
    Unternehmen (KMU)

8
  • Ziele
  • Verbesserung der Gesundheit der europäischen
    Bevölkerung
  • Stärkung der europ. Industrie/Firmen im Bereich
    Gesundheit
  • Blick auf globale Gesundheitsfragen
  • (z.B. Epidemien
  • Schwerpunkte
  • Translationale Forschung (Grundlagenforschung ?
    klinische
    Anwendung)
  • Neue Therapien (Entwicklung und Validierung)
  • Methoden zur Gesundheitsförderung,
    Krankheitsprävention
  • Diagnostische Instrumente und medizinische
    Technologien
  • Effiziente Gesundheitssysteme

Thema 1- Gesundheit (6.050 Mio. Euro)
9
Thema 1 Gesundheit (6.050 Mio. )
Einreichfrist 1. Ausschreibung 19. April
2007 Einreichfrist 2. Ausschreibung 18.
September 2007

10
  • High-throughput research
  • Unifying human and model organism genetic
    variation databases
  • Temporal and spatial proteomics to study
    biological processes relevant to human health
  • Groundbreaking techniques for DNA sequencing and
    genotyping
  • 2. Call
  • SME-driven collaborative research projects for
    developing tools and technologies for
    high-throughput research
  • Detection, Diagnosis and Monitoring
  • Development of a hybrid imaging system
  • Novel optical methodologies for detection,
    diagnosis and monitoring of disease or
    disease-related processes
  • Novel targeted imaging probes for early in vivo
    diagnosis and/or evaluation of response to
    therapy
  • In vivo image-guidance for cell therapy
  • 2. Call
  • Standardisation and improvement of pre-analytical
    procedures for in vitro diagnostics
  • High throughput molecular diagnostics in
    individual patients for genetic diseases with
    heterogeneous clinical presentation

11
  • Predicting suitability, safety and efficacy of
    therapies
  • Thema zum Großteil durch Innovative Medicines
    Initiative (IMI) abgedeckt!
  • Novel alternative testing strategies for use in
    pharmaceutical discovery and development
  • Bottlenecks in reduction, refinement and
    replacement of animal testing in pharmaceutical
    discovery and development
  • Promotion, development, validation, acceptance
    and implementation of QSARs (quantitative
    structure-activity relationship) for toxicology
  • Alternative testing strategies for the assessment
    of the toxicological profile of nanoparticles
    used in medical diagnostics
  • In silico modelling for ADMET outcomes

12
  • Innovative therapeutic approaches and
    interventions
  • Development and production of new generation
    antibodies
  • Innovative approaches for the development of
    vaccines for young children
  • Immunotherapy of human food allergies
  • 2.Call
  • Development of emerging gene therapy tools and
    technologies for clinical application
  • Stem cell lines for cell-based therapies.
  • Development of stem cell culture conditions.
  • Stem cells for kidney regeneration.
  • Adding value to EU stem cell therapy research
    scientific communication and future perspectives.

13
  • Large-scale data gathering
  • Networking biobanking initiatives across Europe
    developing standards and norms for existing and
    future human sample biobanks
  • Molecular epidemiological studies in existing
    well characterised European (and/or other)
    population cohorts
  • Comparative studies of genetic variation in
    humans towards a reference population in Europe
  • Characterisation and variability of the microbial
    communities in the Human Body
  • Structure-function analysis of membrane-transporte
    rs and channels for the identification of
    potential drug target sites
  • High throughput analysis of lipids and
    lipid-protein interactions
  • Genome-wide association studies in mammalian
    non-rodent models for the identification of genes
    relevant to human health and disease

14
  • Systems biology
  • A system approach to eukaryotic unicellular
    organism biology
  • Modelling of T-cell activation
  • Fundamental approaches to stem cell
    differentiation
  • Developing an integrated in vitro, in vivo and
    systems biology modelling approach to
    understanding apoptosis in the context of health
    and disease
  • 2. call
  • Multidisciplinary fundamental genomics and
    molecular biology approaches to study basic
    biological processes relevant to health and
    diseases
  • Coordination and Support Actions in large-scale
    data gathering and systems biology
  • Traditional Chinese Medicine in post-genomic era.
    Specific International Cooperation Action.
    Targeted region China.

15
  • Brain and related diseases
  • Stroke and mechanisms underlying ischemic brain
    damage
  • Coding in neuronal assemblies
  • Neurobiology of anxiety disorders
  • Memory loss underlying mechanisms and therapy
  • From basic spinal mechanisms to spinal cord
    disease and trauma.
  • Neuron-glia interactions in health and disease
  • 2. Call
  • Restorative approaches for therapy of
    neurodegenerative diseases.
  • From mood disorders to experimental models.
  • Neuronal mechanisms of vision and related
    diseases.
  • Childhood and adolescent mental disorders.
    Specific International Cooperation Action. Target
    regions Eastern Europe and Central Asia and
    Western Balkans.

16
  • Human Development and Ageing
  • Novel approaches to reconstitute normal immune
    function at old age.
  • Termination of developmental processes and their
    reactivation in adult life
  • Biomarkers of ageing.
  • Increasing the participation of elderly in
    clinical trials.
  • Research on human development and/or healthy
    ageing across the EU

17
  • Anti-microbial drug resistance including fungal
    pathogens
  • 2. Call
  • Novel targets for drugs against Gram negative
    bacteria.
  • Host-pathogen interactions in infections by
    Streptococcus pneumoniae.
  • An integrated platform for development and
    clinical evaluation of point-of-care diagnostic
    devices for microbial detection, antibiotic
    susceptibility determination and biomarkers
  • Molecular epidemiology to control nosocomial and
    community spreading of highly virulent multi-drug
    resistant strains of bacterial pathogens.
  • Health and economic cost of antimicrobial
    resistance.
  • Conference on genetic and biochemical tools for
    postgenomic physiological analysis of
    Staphylococcus, in particular MRSA.

18
  • HIV, AIDS, malaria and tuberculosis
  • HIV/AIDS Drug Discovery and Preclinical
    Development
  • Highly innovative approaches for research into
    host-pathogen interaction in tuberculosis
  • Development of fast tests for the diagnosis of
    Multi-Drug-Resistant strains of HIV, malaria and
    tuberculosis and of latent tuberculosis infection
    (LTBI).
  • Addressing knowledge gaps in pregnancy malaria.
  • New HIV Vaccines inducing broadly-reactive
    neutralising antibodies.
  • 2. Call
  • Network on HIV and anti-HIV drug resistance
  • HIV and Hepatitis co-infection
  • Blocking the transmission of malaria the
    mosquito vector target.
  • European network for study and clinical
    management of TB drug resistance.
  • Support platform for the development of PRD
    vaccines
  • Highly innovative research in HIV/AIDS, malaria
    and tuberculosis between Indian and European
    partners. (SICA, Targeted Region India)
  • Coordination of European research activities with
    global initiatives, including Public-Private-Partn
    erships (SICA Targeted Regions ICPC).
  • Next generation of researchers for HIV/AIDS,
    malaria, tuberculosis and neglected infectious
    diseases (SICA Targeted Regions ICPC).

19
  • Potentially new and re-emerging epidemics
  • Development of broadly protective influenza
    vaccine candidates.
  • Identifying immunological mechanisms of
    protection for influenza vaccines
  • Standardisation of immunological assays including
    surrogate markers for evaluation of new influenza
    vaccines in clinical trials
  • Innovative point-of-care diagnostic tests for
    influenza.
  • Development of additional treatment strategies
    for patients suffering from highly pathogenic
    influenza.
  • Development of pandemic influenza containment and
    mitigation strategies.
  • Supporting highly innovative inter-disciplinary
    research on influenza.
  • Influenza research in collaboration with Asian
    partners. (SICA, Targeted regions Asia)
  • 2. Call
  • Strengthening research on prediction,
    identification, modelling and surveillance of
    newly emerging infectious diseases in humans.
  • Definition of research needs and priorities in
    Europe in the area of Emerging Infectious
    Epidemics.

20
  • Cancer
  • Translating the knowledge on non-coding RNAs
    linked to the aetiology of cancer into novel
    diagnosis and therapy strategies.
  • Translating clinical omics-technology
    (genomics, proteomics, metabolomics) into
    innovative cancer biomarkers aiding in early
    diagnosis, prognosis and treatment selection of
    cancer patients.
  • Genomic instability and genomic alterations in
    pre-cancerous lesions and/or cancer.
  • Novel cancer screening methods.
  • Optimising research on end of life care of cancer
    patients.
  • Understanding and fighting metastasis.
  • Improving targeted drug delivery to cancer cells
    for cancer therapeutics other than gene therapy
  • Developing high-throughput bioassays and models
    for human cancers in lower species.
  • 2. Call
  • Innovative combination clinical trials for
    multimodal cancer therapy.
  • Role of inflammation in tumour initiation and
    progression.
  • Epidemiology of gene-environment interactions
    involved in carcinogenesis.
  • Translating the hypoxic tumour microenvironment.
  • ERA-NET on optimisation of the use of cancer
    registries for cancer research purposes
  • Studying cancer aetiology in Latin America. (SICA)

21
  • Cardiovascular Disease
  • Molecular basis of the inflammatory response and
    associated vascular remodelling in
    arteriosclerosis.
  • Vascular remodelling in aneurysmal disease.
  • Combating stroke.
  • 2. Call
  • Congenital pathologies affecting the heart.
  • Cell therapies for the treatment of heart
    ischemia.
  • Organ imaging in CVD.
  • Integrating pharmacogenomic approaches into the
    treatment of CVD.

22
  • Diabetes and Obesity
  • Early processes in the pathogenesis of type 1
    diabetes and strategies for early prevention.
  • Combined forms of diabetes in children.
  • Insulin resistance as a key factor in the
    development of diabetes and metabolic syndrome.
  • Pathophysiological mechanisms related to excess
    fat.
  • A road-map for diabetes research.
  • 2. Call
  • Nutritional signals and the development of new
    diabetes/obesity therapeutic agents.
  • Markers and treatment for diabetic neuropathy
    complications.
  • Geno- and phenotypical differentiation of type 2
    subjects and monogenic subjects.
  • Use of beta cell imaging in diabetes mellitus.

23
  • Rare Diseases
  • Natural course and pathophysiology of rare
    diseases.
  • Research capacity-building in the field of rare
    diseases.
  • Other Chronic Diseases
  • Osteoarthritis.
  • Inflammatory bowel disease.
  • Osteoporosis signalling pathways in bone
    formation and homeostasis.
  • Genetic factors of Osteoporosis.
  • Intervertebral disc degeneration prevention and
    repair.
  • Innovative concepts in chronic obstructive
    pulmonary disease pathogenesis (COPD).
  • Hearing impairment and degeneration.
  • Impairment of touch and proprioception at old
    age.
  • Visual impairment and degeneration.
  • 2. Call
  • Understanding and combating age-related muscle
    weakness.
  • Translational research aiming for a treatment of
    urinary incontinence.

24
  • Translating clinical research into clinical
    practice including better use of
  • medicines, and appropriate use of behavioural and
    organisational
  • interventions and health therapies and
    technologies
  • 2.call
  • Implementation of research into healthcare
    practice
  • Self-medication and patient safety
  • Patient Safety Research Network
  • Improving clinical decision making
  • Better use of medicines.
  • Continuity of clinical care.
  • Patient self-management of chronic disease.
  • Quality, solidarity and sustainability of health
    systems

25
  • Enhanced health promotion and disease prevention
  • 2.call
  • Promoting healthy behaviour in children and
    adolescents
  • Interventions addressing the gradient of health
    inequalities
  • Public health interventions addressing the abuse
    of alcohol.
  • Evaluation of suicide prevention strategies
    across and within European countries.
  • Improve vaccination coverage
  • Horizontal Coordination and Support Actions
    across Optimising the Delivery
  • of Health Care to European Citizens
  • 2.call
  • Disease networks of centres of reference.

26
  • Specific International Cooperation Actions for
    Health System Research
  • 2.call
  • Epidemiological investigations into long-term
    trends of population health as consequence of
    socio-economic transitions, including life-style
    induced health problems. SICA (Mediterranean
    Partner countries, Russia, Eastern European and
    Central Asia)
  • Universal and equitable access to health care and
    health financing. SICA (MCP, ACP, Asia and Latin
    America)
  • Health care intervention research optimising
    hospital care. SICA (Western Balkans.)
  • Health care intervention research improving
    pre-natal and maternal care. SICA (ACP and
    Mediterranean Partner Countries)

27
  • Coordination and Support Actions across the Theme
  • Reinforcing the network of National Contact
    Points (NCP) for the Seventh Framework Programme
    under Health Theme by promoting transnational
    co-operation.)
  • Promoting participation of high-technology
    research intensive SMEs, operating in the
    biomedical engineering and other medical
    technology sectorsrelevant to Health Theme.
  • Assessment and valorisation of project outcome
    for hightechnology and research intensive SME
    participating to Framework Programmes of Research
    in the healthcare sector.
  • Science communication actions.
  • Initiatives to foster dialogue and debate on
    health research issues of interest to the public.
  • Studies on the impact of EU legislation on health
    research and related developments and
    applications.
  • 2.call
  • Promotion and facilitation of international
    cooperation in areas relevant to the objectives
    of this theme. (SICA, ICPC)
  • Responding to EU policy needs (2.call)
  • Paediatric medicinal products, Drug safety
    research, Living and work conditions, Health
    statistics, Tobacco Control

28
Technologieplattformen und Gemeinsame
Technologieinitiativen
  • Mobilisierung europäischer Ressourcen im Bereich
    Forschung, technologische Entwicklung und
    Innovation durch Zusammenbringen aller Akteure
    eines definierten Forschungsbereiches (Industrie,
    KMU, Universitäten, Endverbraucher)
  • Industriegetrieben
  • Gemeinsame Definition und Erstellung einer
    strategischen Forschungsagenda (mittel- bis
    langfristig)
  • Input zur Entwicklung der thematischen
    Programme im 7. RP
  • Einige wenige werden als Gemeinsame
    Technologieinitiativen (Joint Technology
    Initiatives) etabliert
  • Neuer Weg zur Realisierung von public-private
    partnerships auf EU-Ebene mit definierter
    rechtlicher Struktur

29
Example Innovative Medicines - en route to a
Joint Technology Initiative
  • Accelerated Development of safe and more
    effective medicines
  • Revitalization of the the biopharmaceutical
    research and development (RD) environment for
    Europe to become more competitive
  • Improving the collaboration between all relevant
    actors from public and private organisations
    (public-private partnerships)
  • Draft and Implementation of a European Research
    Agenda
  • Second version of the Strategic Research
    Agenda published recently
  • First Calls expected for end of 2007/beginning
    of 2008
  • http//europa.eu.int/comm/research/fp6/index_en.cf
    m?p1_innomed
  • http//rp7.ffg.at/RP7.aspx_param_target_is_116120.
    v.aspx

30
  •  Innovative Medicines 
  • 2. version of the  Strategic Research Agenda 
  • 4 main topics
  • Safety
  • Early safety evaluation and risk
    assessment, creation of a European Centre
    for Drug Safety
  • Efficacy
  • Predictive pharmacology, biomarker
    identification and validation, patient
    recruitment and risk assessment
  • Knowledge Management
  • New technologies to control and analyse
    enormous quantities of information in an
    integrative and predictive way
  • Education and Training
  • Bridge gaps in expertise required to
    strengthen the biopharmaceutical RD process,
    creation of a European Medicines Research Academy

31
  • Technologieplattform
  •  Innovative Medicines 
  • Contact in Austria
  • Univ. Prof. Dr. Hans Georg Eichler,
  • Vice Rector of the Medical University in
    Vienna
  • vr_forschung_at_meduniwien.ac.at

32
Relevante Themen der 1. Ausschreibungen aus
anderen Bereichen
  • Food, Agriculture, Fisheries and Biotechnology
  • e.g. Fork to farm Food (including seafood),
    health and well being
  • Information and Communication Technologies
  • Objective ICT-2007.5.3 Virtual Physiological
    Human
  • Nanosciences, Nanotechnologies, Materials and new
    Production
  • Technologies
  • Creation of a critical and commented database on
    the health,
  • safety and environmental impact of nanoparticles
  • Substantial innovation in the European medical
    industry development of
  • nanotechnology-based systems for in-vivo
    diagnosis and therapy (in
  • Coordination with topic HEALTH-2007-2.4.1-7 and
    HEALTH-2007-1.2-3 in
  • Theme 1 "Health")
  • Environment Environment and Health
  • Security Topic SEC-2007-1.3-05 Water
    distribution surveillance Critical
    Infrastructure
  • Protection

33
Inhalt
  • Das 7. Rahmenprogramm im Überblick
  • Themen der ersten Ausschreibungen zu Gesundheit
  • Forschung zugunsten kleiner und mittlerer
    Unternehmen (KMU)

34
Zusammenarbeit zwischen Industrie und
FE-Dienstleistern
  • Forschung zugunsten von Kleinen und Mittleren
    Unternehmen (KMUs)
  • Forschung zugunsten von KMU-Verbänden

35
Kennzeichen
  • Themen Bottom up Ansatz (gesamtes Feld der
    Wissenschaft Technologie)
  • KMUs/KMU-Verbände lagern Forschung
    technologische Entwicklung aus
  • Flexibilität bezüglich der intellectual property
    rights

36
Aktivitäten
  • Forschungs- und technologische Entwicklungsaktivit
    äten
  • Demonstrationsaktivitäten
  • Andere Aktivitäten (Trainings, dissemination
    activities)
  • Management-Aktivitäten

37
Research for SMEs
Project participation scheme
RTD-performers
Industry
at least 3 SMEs from at least 3 countries (MS,
AS)
at least 2 universities research
centres industrial companies research performing
SMEs
38
Research for SME-Associations
Project participation scheme
Industry
RTD-performers
at least 2 universities research
centres industrial companies research performing
SMEs
at least 3 SME-Ass. from at least 3 countries
(MS, AS) or 1 European SME-Ass. at least 2 SMEs
39
Research for SMEs/ SME-Associations
Research for SMEs Research for SME associations
Duration 1 - 2 years 2 - 3 years
Number of partners 5 - 10 10 -15
Total budget 0.5 1.5 Million 1.5 4 Million
Activities RD, demonstration, management, other activities RD, demonstration, management, other activities
Share of RD carried out by RTD performers
60 Source European Commission
40
Einreichfristen
  • Research for SMEs FP7-SME-2007-1
  • Einreichfrist
    4.September 200
  • Research for SME Associations
    FP7-SME-2007-2

  • Einreichfrist 1. Juni 2007
  • Kontakt Dr. Ines Haberl, ines.haberl_at_ffg.at
  • http//rp7.ffg.at/RP7.aspx
  • http//cordis.europa.eu/en/home.html

41
Wichtige Dokumente zur Vorbereitung
  • Arbeitsprogramme Annexes
  • Guide for Applicants
  • Rules for Participation
  • Model Grant Agreement
  • Leitfaden/Formular für Anbahnungsfinanzierung
  • rp7.ffg.at -gt Services der FFG

42
Kontaktieren Sie uns! Ihre Ansprechpartner für
Life Sciences in der FFG/ Bereich Europäische und
Internationale Programme
  • Mag. Birgit Steininger
  • Leiterin des Referats für Biowissenschaften,
  • Nationale Kontaktstelle für Lebensmittel,
    Landwirtschaft und Biotechnologie (DW 4101)
  • birgit.steininger_at_ffg.at
  • Dr. Ylva Huber
  • Nationale Kontaktstelle für Gesundheit (DW 4102)
  • ylva.huber_at_ffg.at
  • Dr. Ines Haberl
  • Nationale Kontaktstelle für KMUs (DW 4103)
  • Ines.haberl_at_ffg.at
  • e-mail vorname.nachname_at_ffg
    .at, Tel 43/57755-Durchwahl

43
Vielen Dank für Ihre Aufmerksamkeit viel
Erfolg für Ihre Projekte im 7. Rahmenprogramm!
About PowerShow.com